We are excited to congratulate the Hong Kong Med-Tech Association (HKMTA) on their new name, reflecting a stronger focus on technology. Our President and Managing Director, Jennifer Che, along with Principal Pauli Wong, were thrilled to celebrate this significant milestone with the organization at the recent HKMHDIA Medical Fair Forum.

Pauli, the official IP Advisor to HKMTA, joined Jennifer, one of the keynote speakers at the event, who shared about the importance of a well-thought-out intellectual property strategy for healthcare inventions. Jennifer emphasized the challenges of protecting biomedical products that operate at the intersection of regulatory affairs, IP, trade secret, and data privacy, particularly in the complex, multijurisdictional landscape of the Greater Bay Area (GBA). The event fostered valuable discussions on navigating these complexities, reinforcing our commitment to helping innovators safeguard their groundbreaking ideas.

Our Past Events

Recommended Insights

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

10 November 2023
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]
Top crossarrow-right